VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

VārdsVRTXON

ReitingsNo.3663

Tirgus kapitalizācija$0.00

Tirgus kapitalizācija pie pilnas emisijas$0.00

Tirgus daļa%

Tirdzniecības apjoms/tirgus kapitalizācija (24H)14,838,345.18%

Apjoms apgrozībā4.93330357

Maksimālais apjoms0

Kopējais apjoms4.93330357

Apgrozības koeficients%

Izdošanas datums--

Cena, par kuru aktīvs tika pirmo reizi izdots--

Visu laiku augstākā cena466.35223147502205,2026-03-26

Zemākās cena414.92035330237934,2026-05-05

Publiska blokķēdeETH

IevadsVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Nozare

Sociālie tīkli

• Oficiālā vietne
• Bloku pārlūks

etfindex:mc_etfindex_sourceAtruna: Datus nodrošina cmc, un šie dati nav uzskatāmi par ieguldījuma veikšanas ieteikumu.